# Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

> **NCT04668690** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 193 (actual)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome Injection
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT04668690
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-13
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04668690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04668690, "Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04668690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*